| Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. | |
| | |
MedLine Citation:
|
PMID: 17878209 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate whether clinical and radiographic disease control can be achieved and maintained in patients with early, active rheumatoid arthritis (RA) during the second year of aggressive treatment with conventional disease-modifying antirheumatic drugs (DMARDs) and intra-articular corticosteroid. This paper presents the results of the second year of the randomised, controlled double-blind CIMESTRA (Ciclosporine, Methotrexate, Steroid in RA) study. METHODS: 160 patients with early RA (duration <6 months) were randomised to receive intra-articular betamethasone in any swollen joint in combination with step-up treatment with either methotrexate and placebo-ciclosporine (monotherapy) or methotrexate plus ciclosporine (combination therapy) during the first 76 weeks. At week 68 hydroxychlorochine 200 mg daily was added. From week 76-104 ciclosporine/placebo-ciclosporine was tapered to zero. RESULTS: American College of Rheumatology 20% improvement (ACR20), ACR50 and ACR70 levels were achieved in 88%, 79% and 59% of patients in the combination vs 72%, 62% and 54% in the monotherapy group (p = 0.03, 0.02 and 0.6 between groups). The patients globally declined from 50 to 12 vs 52 to 9, with 51% and 50% in Disease Activity Score (DAS) remission, respectively. Mean (SD) progressions in total Sharp-van der Heijde scores were 1.42 (3.52) and 2.03 (5.86) in combination and monotherapy groups, respectively (not significant). Serum creatinine levels increased by 7% in the combination group (4% in monotherapy), but hypertension was not more prevalent. CONCLUSION: Continuous methotrexate and intra-articular corticosteroid treatment resulted in excellent clinical response and disease control at 2 years, and the radiographic erosive progression was minimal. Addition of ciclosporine during the first 76 weeks resulted in significantly better ACR20 and ACR50 responses, but did not have any additional effect on remission rate and radiographic outcome. |
| | |
Authors:
|
M L Hetland; K Stengaard-Pedersen; P Junker; T Lottenburger; I Hansen; L S Andersen; U Tarp; A Svendsen; J K Pedersen; H Skjødt; U B Lauridsen; T Ellingsen; G V O Hansen; H Lindegaard; A Vestergaard; A G Jurik; M Østergaard; K Hørslev-Petersen; |
Related Documents
:
|
18050189 - Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study ... 23552589 - Effects of dexmedetomidine on succinylcholine-induced myalgia in the early postoperativ... 15096329 - Estimated prediagnosis radiological progression: an important tool for studying the eff... 9779839 - Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after ra... 1445449 - The treatment of wegener's granulomatosis with glucocorticoids and methotrexate. 23207829 - Evolution of glycolipid profile after sleeve gastrectomy vs. roux-en-y gastric bypass: ... 17760539 - Coronally positioned flap for root coverage in smokers and non-smokers: stability of ou... 3219509 - Is extracorporeal shockwave lithotripsy suitable treatment for lower ureteric stones? 12381639 - Surgical closure of atrial septal defects in adults: effect of age at operation on outc... |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2007-09-18 |
Journal Detail:
|
Title: Annals of the rheumatic diseases Volume: 67 ISSN: 1468-2060 ISO Abbreviation: Ann. Rheum. Dis. Publication Date: 2008 Jun |
Date Detail:
|
Created Date: 2008-05-13 Completed Date: 2008-06-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372355 Medline TA: Ann Rheum Dis Country: England |
Other Details:
|
Languages: eng Pagination: 815-22 Citation Subset: IM |
Affiliation:
|
Department of Rheumatology, Copenhagen University Hospital, Hvidovre, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antirheumatic Agents / therapeutic use* Arthritis, Rheumatoid / drug therapy*, radiography Arthrography Betamethasone / administration & dosage Combined Modality Therapy Cyclosporine / therapeutic use Disease Progression Drug Therapy, Combination Female Glucocorticoids / therapeutic use* Humans Hydroxychloroquine / therapeutic use Immunosuppressive Agents / therapeutic use* Injections, Intra-Articular Male Methotrexate / therapeutic use Middle Aged Severity of Illness Index Statistics, Nonparametric Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/Glucocorticoids; 0/Immunosuppressive Agents; 118-42-3/Hydroxychloroquine; 378-44-9/Betamethasone; 59-05-2/Methotrexate; 59865-13-3/Cyclosporine |
| Investigator | |
Investigator/Affiliation:
|
T Lorenzen / ; S H Jensen / ; J Pødenphant / ; H Bendtsen / ; K L Faarvang / ; M S Hansen / ; T M Hansen / ; H Nielsen / ; S Jacobsen / ; O Majgaard / ; J Beier / ; L Ejstrup / ; J B Knudsen / ; H Laustrup / ; N S Krogh / ; Ap S Zitelab / ; J Vallø / ; H S Thomsen / ; B Ejbjerg / ; T Torfing / ; G Bukh / ; J Frederiksen / ; P Rasmussen / ; K Theilgård / ; L Gerdes / ; H Holm / ; K B Lorentzen / ; B Pedersen-Zbinden / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Current management of biliary atresia.
Next Document: Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome.